{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:04:01Z","timestamp":1759089841828,"version":"3.40.5"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"am","delay-in-days":302,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["UH3 AR075336"],"award-info":[{"award-number":["UH3 AR075336"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01 HD099486"],"award-info":[{"award-number":["R01 HD099486"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["R01 HL089221","K99\/R00 HL161420\\u201301"],"award-info":[{"award-number":["R01 HL089221","K99\/R00 HL161420\\u201301"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Physiology & Neurobiology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.resp.2025.104433","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T23:19:05Z","timestamp":1745623145000},"page":"104433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["GAA replacement improves respiratory muscle, neural, and alveolar pathology in the pompe mouse"],"prefix":"10.1016","volume":"335","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5249-7176","authenticated-orcid":false,"given":"Angela L.","family":"Roger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"El Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith L.","family":"Huston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Kehoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davina","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mainur","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Scarrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Benkert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aravind","family":"Asokan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1775-1156","authenticated-orcid":false,"given":"Mai K.","family":"ElMallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resp.2025.104433_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/atm.2019.05.56","article-title":"Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy","volume":"7","author":"Byrne","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.resp.2025.104433_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2011.02.004","article-title":"Pompe disease: design, methodology, and early findings from the Pompe Registry","volume":"103","author":"Byrne","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.resp.2025.104433_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2024.1309146","article-title":"Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa","volume":"15","author":"Carter","year":"2024","journal-title":"Front. Genet."},{"key":"10.1016\/j.resp.2025.104433_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/humc.2015.068","article-title":"Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in pompe disease: preclinical to clinical planning","volume":"26","author":"Corti","year":"2015","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.resp.2025.104433_bib5","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1073\/pnas.76.9.4526","article-title":"Genetics of type II glycogenosis: assignment of the human gene for acid alpha-glucosidase to chromosome 17","volume":"76","author":"D\u2019Ancona","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.resp.2025.104433_bib6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.resp.2025.104433_bib7","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Lysosomal storage disease 2: Pompe\u2019s disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.resp.2025.104433_bib8","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.resp.2025.104433_bib9","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2147\/TCRM.S362871","article-title":"Monitoring and management of respiratory function in Pompe disease: current perspectives","volume":"19","author":"El Haddad","year":"2023","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.resp.2025.104433_bib10","doi-asserted-by":"crossref","first-page":"L288","DOI":"10.1152\/ajplung.00032.2023","article-title":"GAA deficiency disrupts distal airway cells in Pompe disease","volume":"325","author":"El Haddad","year":"2023","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.resp.2025.104433_bib11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ppul.24621","article-title":"Pulmonary outcome measures in long-term survivors of infantile Pompe disease on enzyme replacement therapy: a case series","volume":"55","author":"ElMallah","year":"2020","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.resp.2025.104433_bib12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/hgtb.2012.009","article-title":"Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9","volume":"23","author":"ElMallah","year":"2012","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.resp.2025.104433_bib13","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/mt.2013.282","article-title":"Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice","volume":"22","author":"ElMallah","year":"2014","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.resp.2025.104433_bib14","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/mt.2013.96","article-title":"Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease","volume":"21","author":"Falk","year":"2013","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.resp.2025.104433_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.7","article-title":"Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice","volume":"2","author":"Falk","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.resp.2025.104433_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/hmg\/ddu476","article-title":"Peripheral nerve and neuromuscular junction pathology in Pompe disease","volume":"24","author":"Falk","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.resp.2025.104433_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.resp.2013.06.007","article-title":"The respiratory neuromuscular system in Pompe disease","volume":"189","author":"Fuller","year":"2013","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.resp.2025.104433_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1152\/jn.00190.2021","article-title":"Case studies in neuroscience: neuropathology and diaphragm dysfunction in ventilatory failure from late-onset Pompe disease","volume":"126","author":"Fuller","year":"2021","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.resp.2025.104433_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21062256","article-title":"The respiratory phenotype of pompe disease mouse models","volume":"21","author":"Fusco","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.resp.2025.104433_bib20","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1038\/s41467-022-33745-4","article-title":"Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing","volume":"13","author":"Gonzalez","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.resp.2025.104433_bib21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors","volume":"22","author":"Gray","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.resp.2025.104433_bib22","first-page":"1787","article-title":"A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia","author":"Guyenet","year":"2010","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.resp.2025.104433_bib23","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ymgme.2012.05.007","article-title":"Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature","volume":"106","author":"Hobson-Webb","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.resp.2025.104433_bib24","doi-asserted-by":"crossref","first-page":"L873","DOI":"10.1152\/ajplung.00568.2016","article-title":"Airway smooth muscle dysfunction in Pompe (Gaa-\/-) mice","volume":"312","author":"Keeler","year":"2017","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.resp.2025.104433_bib25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.omtm.2019.12.007","article-title":"Intralingual and intrapleural AAV gene therapy prolongs survival in a SOD1 ALS mouse model","volume":"17","author":"Keeler","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.resp.2025.104433_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/hum.2018.016","article-title":"Systemic delivery of AAVB1-GAA clears glycogen and prolongs survival in a mouse model of Pompe disease","volume":"30","author":"Keeler","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.resp.2025.104433_bib27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.resp.2025.104433_bib28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/atm.2019.05.02","article-title":"Liver depot gene therapy for Pompe disease","volume":"7","author":"Kishnani","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.resp.2025.104433_bib29","first-page":"267","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet. Med. Off. J. Am. Coll. Med. Genet."},{"key":"10.1016\/j.resp.2025.104433_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/humu.20745","article-title":"Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating","volume":"29","author":"Kroos","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.resp.2025.104433_bib31","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1007\/s12035-017-0763-4","article-title":"A neuron-specific gene therapy relieves motor deficits in Pompe disease mice","volume":"55","author":"Lee","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.resp.2025.104433_bib32","first-page":"464","article-title":"Current avenues of gene therapy in Pompe disease","volume":"36","author":"Leon-Astudillo","year":"2023","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.resp.2025.104433_bib33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.omtm.2019.01.006","article-title":"Intravenous injection of an AAV-PHP.B vector encoding human acid \u03b1-glucosidase rescues both muscle and CNS defects in murine Pompe disease","volume":"12","author":"Lim","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.resp.2025.104433_bib34","first-page":"18","article-title":"A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease","volume":"13","author":"Lim","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.resp.2025.104433_bib35","doi-asserted-by":"crossref","first-page":"9641","DOI":"10.1073\/pnas.83.24.9641","article-title":"Isolation of a cDNA for human acid alpha-glucosidase and detection of genetic heterogeneity for mRNA in three alpha-glucosidase-deficient patients","volume":"83","author":"Martiniuk","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.resp.2025.104433_bib36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1540\/jsmr.57.8","article-title":"Glycogen accumulation in smooth muscle of a Pompe disease mouse model","volume":"57","author":"McCall","year":"2021","journal-title":"J. Smooth Muscle Res. Nihon Heikatsukin Gakkai kikanshi"},{"key":"10.1016\/j.resp.2025.104433_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.resp.2020.103525","article-title":"Respiratory pathology in the Optn-\/- mouse model of Amyotrophic Lateral Sclerosis","volume":"282","author":"McCall","year":"2020","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.resp.2025.104433_bib38","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3390\/ijms20030751","article-title":"Macroglossia, motor neuron pathology, and airway malacia contribute to respiratory insufficiency in Pompe disease: a commentary on molecular pathways and respiratory involvement in lysosomal storage diseases","volume":"20","author":"McCall","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.resp.2025.104433_bib39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1540\/jsmr.54.100","article-title":"The impact of Pompe disease on smooth muscle: a review","volume":"54","author":"McCall","year":"2018","journal-title":"J. Smooth Muscle Res. Nihon Heikatsukin Gakkai kikanshi"},{"key":"10.1016\/j.resp.2025.104433_bib40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1566523219666190621113807","article-title":"Reduction of autophagic accumulation in pompe disease mouse model following gene therapy","volume":"19","author":"McCall","year":"2019","journal-title":"Curr. gene Ther."},{"key":"10.1016\/j.resp.2025.104433_bib41","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 start trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.resp.2025.104433_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1750-1172-8-90","article-title":"Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy","volume":"8","author":"Prater","year":"2013","journal-title":"Orphanet J. rare Dis."},{"key":"10.1016\/j.resp.2025.104433_bib43","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.resp.2025.104433_bib44","first-page":"1","article-title":"What\u2019s new and what\u2019s next for gene therapy in Pompe disease?","author":"Roger","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.resp.2025.104433_bib45","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/archdischild-2020-320908","article-title":"Gene therapy for neuromuscular disorders: prospects and ethics","volume":"107","author":"Ryan","year":"2022","journal-title":"Arch. Dis. Child"},{"key":"10.1016\/j.resp.2025.104433_bib46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1590\/s1806-37562015000000343","article-title":"Respiratory manifestations in late-onset Pompe disease: a case series conducted in Brazil","volume":"43","author":"Sixel","year":"2017","journal-title":"J. Bras. Pneumol."},{"key":"10.1016\/j.resp.2025.104433_bib47","doi-asserted-by":"crossref","first-page":"473","DOI":"10.5114\/bta.2021.111111","article-title":"Retrograde capabilities of adeno-associated virus vectors in the central nervous system","volume":"102","author":"Surdyka","year":"2021","journal-title":"Biotechnologia"},{"key":"10.1016\/j.resp.2025.104433_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16292","article-title":"Real-life effectiveness 1 year after switching to avalglucosidase alfa in late-onset Pompe disease patients worsening on alglucosidase alfa therapy: a French cohort study","volume":"31","author":"Tard","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.resp.2025.104433_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.108121","article-title":"Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-na\u00efve adults with late-onset Pompe disease compared with alglucosidase alfa: meaningful change analyses from the Phase 3 COMET trial","volume":"141","author":"Toscano","year":"2024","journal-title":"Mol. Genet. Metab."}],"container-title":["Respiratory Physiology & Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569904825000448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569904825000448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T23:01:46Z","timestamp":1746831706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569904825000448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":49,"alternative-id":["S1569904825000448"],"URL":"https:\/\/doi.org\/10.1016\/j.resp.2025.104433","relation":{},"ISSN":["1569-9048"],"issn-type":[{"type":"print","value":"1569-9048"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GAA replacement improves respiratory muscle, neural, and alveolar pathology in the pompe mouse","name":"articletitle","label":"Article Title"},{"value":"Respiratory Physiology & Neurobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resp.2025.104433","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104433"}}